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ABSTRACT
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Immunoglobulin A (IgA) vasculitis (IgAV), formerly Henoch-Schönlein purpura, is a systemic
small-vessel  vasculitis  characterised  by  IgA1-dominant  immune  deposits.  Its  clinical
manifestations  include  purpura,  gastrointestinal  involvement,  arthralgias/arthritis,  and
glomerulonephritis.1 IgAV is the most common vasculitis  in children, whereas it  is  rare in
adults. Childhood-onset IgAV usually has a benign course only requiring supportive care. In
adults, its prognosis is worse, particularly because of the high frequency and severity of renal
involvement; indeed, adult-onset IgAV leads to advanced chronic kidney disease (CKD) or
end-stage renal disease (ESRD) in 10-30% of the cases.2 
The  treatment  of  adult-onset  IgAV  is  still  a  matter  of  debate.  Glucocorticoids  and
immunosuppressive  drugs  are  routinely  used  especially  in  patients  with  organ-  or  life-
threatening manifestations.3 However, the efficacy of these treatments is controversial. In the
only randomised trial performed in adult-onset IgAV, the addition of cyclophosphamide to
glucocorticoids failed to provide any clear benefit.4 Other immunosuppressive agents such as
azathioprine, mycophenolate mofetil or cyclosporine have only been reported in anecdotal
cases.3,5 Therefore, there is an unmet need for effective therapies in adult-onset IgAV.
The anti-CD20 monoclonal antibody rituximab (RTX) has become a standard treatment for
remission-induction  and  remission-maintenance  in  patients  with  small-vessel  vasculitides
such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.6,7 RTX induces B-
cell  depletion and thus dampens the expansion of  plasma cells that  produce pathogenic
autoantibodies.  RTX  can  also  impair  antigen-presentation  by  B-cells  or  reduce  B  cell-
mediated stimulation of T-cells and other inflammatory cell types.6 Recently, a few reports
have shown that RTX may be effective for adult-onset IgAV, but they were based on single
cases or small case series including up to five patients.8-10 In this multicentre, observational
study, we analyse the effectiveness and safety of RTX in adult-onset IgAV patients who were
either  relapsing/refractory  or  had  contraindications  to  conventional
glucocorticoid/immunosuppressive therapy. 
Twenty-two  patients  were  included  in  this  study.  Six  cases  were  described  in  previous
papers;8,10 the data presented here regarding these six patients are based on a longer follow-
up  than  that  originally  reported.  Of  the  22  patients,  12  were  men;  their  median  age  at
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diagnosis  was  37.5  years  (interquartile  range,  IQR,  22.8–49.8).  At  diagnosis,  the  most
frequent clinical manifestation was purpura (21 patients, 95.5%); it predominantly affected
the  lower  limbs  and  was  necrotic  or  bullous  in  six  cases  (27.3%).  Gastrointestinal
involvement was found in 18 patients (81.8%); all of them experienced abdominal pain and
seven (39%) gastrointestinal haemorrhage. Twenty patients (90.9%) had kidney involvement.
The median estimated glomerular filtration rate (eGFR) was 76 ml/min/1.73m2 (IQR 65–104),
and the median 24h-proteinuria 1900 mg (IQR 580–3275) (table 1). One patient was dialysis-
dependent at diagnosis but became dialysis-free after initial therapy (before RTX). Fifteen
patients (68.2%) underwent kidney biopsy, which confirmed IgAV in all cases. A diffuse endo-
and/or  extra-capillary  IgAV-glomerulonephritis  (classes  3-4)  was  observed  in  nine  cases
(60%). At diagnosis, disease activity assessment showed a median Birmingham Vasculitis
Activity Score (BVAS) of 16.5 (IQR 13.0–23.8) (table 1).
Sixteen patients (73%) had received other treatments prior to RTX: all of them had received
glucocorticoids,  alone  or  combined  with  cyclophosphamide,  azathioprine,  mycophenolate
mofetil or other drugs (table 1). These 16 patients received RTX (only one as monotherapy)
for  refractory or  relapsing disease.  The remaining six  patients  received RTX as first-line
therapy (five as monotherapy and one together with low-dose glucocorticoids) because they
had contraindications to standard-dose glucocorticoids or other immunosuppressive agents.
Overall, 16 patients received RTX as add-on therapy while six as monotherapy.
At RTX initiation, 18 patients (81.8%) had skin manifestations, 15 (68.2%) gastrointestinal
involvement, 18 (81.8%) kidney involvement, and 16 (72.7%) arthritis and/or arthralgia. The
median BVAS was 15.0 (IQR 9.5–19.8); the median eGFR was 82 ml/min/1.73m2 (IQR 65-
101) and the median 24h-proteinuria 1700 mg (IQR 750-2375) (table 2). 
One  month  after  RTX,  10  patients  (45.5%)  had  achieved  remission;  BVAS  significantly
decreased (p=0.0005) (figure 1). At month 6, 16 patients (72.7%) were in remission and six
(17.3%)  had  active  disease  (three  because  of  persisting  disease  and  three  because  of
relapse after remission) (table 2); as compared with baseline, BVAS and prednisone dose
significantly  decreased  (p=0.0008  and  p=0.03,  respectively).  At  month  12,  16  patients
(72.7%) were in remission and six (17.3%) had active disease (persistent disease in five and
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relapse in  one);  significant  reductions  vs.  baseline  were observed for  BVAS (p=0.0005),
proteinuria  (p=0.001),  CRP (p=0.0007),  and  prednisone  dose  (p=0.01)  (figure  1).  Thus,
during the first  12 months after RTX, remission was achieved by 20 patients (cumulative
incidence of remission 90.9%), four of whom relapsed.
The median follow-up from the start of RTX was 24 months (IQR 18-48). At last follow-up, 18
patients were in remission, three had active disease, and one was deceased (month 60). Of
the  patients  in  remission,  five  were  taking  low-dose  glucocorticoids  (2.5-5  mg/day  of
prednisone). Significant reductions from RTX initiation through last follow-up were observed
for BVAS (p<0.0001),  24h-proteinuria (p<0.0001),  CRP (p=0.0005),  and prednisone dose
(p<0.0001) (figure 1). eGFR did not change significantly. At last follow-up, one patient had
reached ESRD requiring hemodialysis (month 13 after RTX), one had stage 4 CKD, four had
24h-proteinuria>1g;  eight  patients  were  taking  ACE-inhibitors  or  angiotensin-receptor
blockers. Microhematuria persisted in eight patients.
When considering the entire follow-up, we recorded relapses in seven of the 20 patients
(35%) who had achieved remission. Relapses occurred within a median of 12 months (IQR
6.5-15) after RTX; they involved the kidney in four cases, the gastrointestinal tract in one and
the skin in two. Of the four patients with kidney relapses, three were successfully re-treated
with RTX, while one received ACE-inhibitors and then progressed to ESRD. The two patients
with skin relapses were successfully treated with either sulfasalazine (one case) or low-dose
glucocorticoids  (one  case);  the  patient  with  gastrointestinal  relapse  also  responded  to
resumption of low-dose glucocorticoids.
Circulating CD19+ B-cell levels were not systematically tested and were only available for 11
patients,  all  of  whom achieved  B-cell  depletion  (<0.01x109 cells/L)  after  RTX;  given  the
paucity of data, we could not establish any association between B-cell return and relapse. 
RTX therapy was generally well tolerated. Two patients experienced infusion reactions: one
developed urticaria (grade 3) which responded to oral steroids, while the other developed
mild and self-limited dyspnoea (grade 2). These reactions did not preclude subsequent drug
infusions. One patient died because of advanced liver cirrhosis (of undetermined aetiology)
and pneumonia (month 60 after RTX), but this fatal event was probably unrelated to RTX,
given the long period of time elapsed since RTX administration. 
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Adult-onset IgAV is a rare, often severe, small-vessel vasculitis; if left untreated, it usually
has  an  adverse  prognosis.2 Current  treatments,  including  high-dose  glucocorticoids  and
cyclophosphamide, are only partially effective and their toxicity may be high.3,4  Our results
identify  RTX  as  an  effective  therapeutic  option.  In  our  study,  RTX  was  given  for
refractory/relapsing disease or as first-line therapy when conventional immunosuppressive
agents were contraindicated.  The remission rate after  RTX was 91%, with most  patients
achieving remission within six months of RTX therapy. Remission was defined on the basis of
the BVAS,  a widely  used score for  disease activity  assessment in  systemic vasculitides.
However,  other  parameters  such  as  CRP levels  and  prednisone  dose  also  significantly
declined  after  RTX.  Renal  outcomes  were  good:  although  eGFR  remained  stable,  the
reduction in proteinuria was highly significant (approximately 5-fold at end of follow-up vs.
baseline). Only one patient reached ESRD and one developed stage 4 CKD.
Relapses  were  common  (relapse  rate  35%)  after  RTX-induced  remission;  their  clinical
presentation  was  variable,  and  in  severe  cases  re-treatment  with  RTX proved  effective.
Overall, RTX was well tolerated; no major treatment-related adverse events were recorded.
The  potential  mechanisms  of  action  of  RTX  in  IgAV  are  only  speculative.  As  in  IgA
nephropathy,11 also  in  IgAV immune-complexes  containing  galactose-deficient  IgA1  (Gd-
IgA1)  are  thought  to  accumulate  in  target  organs and  initiate  tissue damage.  We could
neither measure serum Gd-IgA1 nor Gd-IgA1-containing immune-complexes; total serum IgA
levels, available in 17/22 patients, showed a slight, progressive reduction after RTX (p=0.03)
(supplementary figure 1). However, the slow kinetics and the little extent of IgA reduction did
not seem to mirror the clinical activity of RTX. We also performed immunohistochemistry on
renal and skin biopsies of IgAV patients (supplementary figure 2) to investigate which cell
types infiltrate target  tissues:  CD20+ B-cells  were either absent  or  scarce,  whereas most
infiltrating  cells  were CD3+  T-cells  or  CD163+ macrophages.  Thus,  although it  cannot  be
excluded that  RTX in IgAV reduces the expansion of  IgA-producing plasma cells  or  hits
tissue-infiltrating B-cells, its therapeutic efficacy most likely results from the impairment of
other  B-cell  functions  such  as  antigen-presentation  and  T-cell  co-stimulation,  as  already
postulated in ANCA-associated vasculitis and other autoimmune conditions.12-13
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Our study has limitations, mainly related to its retrospective nature and the relatively small
sample size. However, it still represents the largest reported experience on the use of RTX in
adult-onset IgAV. In conclusion, in our cohort of adult-onset IgAV patients, RTX effectively
induced disease remission, allowed glucocorticoid tapering and was well tolerated. Larger,
controlled studies are warranted to clarify its role in the management of this rare condition. 
CONCISE METHODS
Patients and treatment
We reviewed the clinical records of all patients with adult-onset IgAV treated with RTX at nine
different  Vasculitis  Centres  in  Europe.  The  diagnosis  of  IgAV was  based  on  the  1990
American College of Rheumatology criteria14 and the 2012 revised Chapel Hill Consensus
Conference nomenclature.1 All patients had to have a biopsy-proven diagnosis of IgAV. The
patients were included if: i) their age at IgAV diagnosis was >18 years; ii) they had severe
involvement of at least one organ (including biopsy-proven IgAV-related nephritis class III-IV;2
gastrointestinal involvement with haemorrhage, ischemia, perforation and/or abdominal pain
unresponsive  to  common  analgesics  and  lasting  for  >24h;  pulmonary  haemorrhage,
episcleritis, cardiac and central nervous system involvement); iii) other systemic autoimmune
or neoplastic diseases were excluded; iv) RTX was given for the treatment of relapsing or
refractory  disease  or  because  there  were  contraindications  to  the  use  of  standard-dose
glucocorticoids and/or conventional immunosuppressants. Allowed RTX schedules included
375 mg/m2/week for  four consecutive weeks or 1000 mgx2 given two weeks apart;  RTX
could be given alone or on top of other immunosuppressive therapies. Glucocorticoids and
other immunosuppressants were tapered or withdrawn according to local practice. RTX was
obtained  by  local  hospital  pharmacies  for  off-label  use;  all  patients  signed  an  informed
consent. The study was performed in accordance with the declaration of Helsinki.
Data collection and disease activity assessment
We retrieved data regarding patient demographics, clinical manifestations, disease duration
and treatments prior to RTX therapy and during the post-RTX follow-up, and reviewed all the
pathology reports of diagnostic biopsies. With regards to the post-treatment follow-up, we
collected clinical and serological data at specific time-points (months 1, 6, 12, and last follow-
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up). eGFR was calculated using the CKD-EPI formula. Information regarding any type of
adverse  events  was  also  collected;  adverse  events  were  graded  using  the  Common
Terminology Criteria for Adverse Events version 4.0.15 Disease activity was evaluated using
the Birmingham Vasculitis Activity Score (BVAS), version 3.16 This score refers to new or
worsening symptoms due to vasculitis activity, with higher scores indicating a more active
disease. Remission was defined by BVAS=0, or BVAS≤5 if all scores were due to persistent
haematuria or proteinuria in the presence of stable or improving renal function. Relapses
were  defined  as  an  increase  in  disease  activity  requiring  the  reinstitution  of
glucocorticoids/other immunosuppressants or  a significant  increase in  glucocorticoid dose
(>50% for prednisone doses ≥15 mg/day or >100% for doses ≤12.5 mg/day).
Renal biopsy
Renal biopsy findings compatible with a diagnosis of IgAV-nephritis were classified as follows
according to Pillebout  et al:2  class 1, mesangiopathic glomerulonephritis; class 2, focal and
segmental glomerulonephritis (segmental endo- and/or extra-capillary proliferation involving
less  than  50%  of  the  glomeruli);  class  3,  diffuse  and  severe  endocapillary  proliferative
glomerulonephritis;  class  4,  endo-  and  extra-capillary  glomerulonephritis;  class  5,  global
glomerular sclerosis involving >90% of the glomeruli. 
Statistical analysis
Continuous variables were expressed as median and IQR, while categorical  variables as
n(%). Variations of continuous variables between two time-points were assessed using the
Wilcoxon’s  test.  Variations  in  continuous  variables  across  different  time-points  (baseline,
month 1, month 6, month 12, last follow-up) were assessed using Friedman’s test. p values
were corrected using Dunn’s test for multiple comparisons. Corrected p values <0.05 were
considered statistically significant.  Statistical analysis was performed using GraphPad Prism
5.
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Table 1. Main characteristics of the 22 patients with IgA vasculitis enrolled in the study
n=22
Male gender, n (%) 12 (54.5)
Age at diagnosis, median (IQR)- years 37.5 (22.8-49.8)
Organ involvement at diagnosis, n (%)
     Skin 21 (95.5)
     Gastro-intestinal 18 (81.8)
     Kidney 20 (90.9)
     Joint 17 (77.3)
     Other sites* 1 (4.5)
BVAS, median (IQR) 16.5 (13.0-23.8)
eGFR (CKD-EPI), median (IQR)- ml/min/1.73m2 76.0 (65.0-104.0)
Proteinuria, median (IQR)- mg/24h 1900 (580-3275)
Kidney biopsy¶, n (%) 15 (68.2)
     Class I 4/15 (26.7)
     Class II 2/15 (13.3)
     Class III 6/15 (40.0)
     Class IV 3/15 (20.0)
Treatments before RTX, n (%)
     Glucocorticoids 16 (72.7)
     Cyclophosphamide 7 (31.8)
     Azathioprine 7 (31.8)
     Mycophenolate mofetil 9 (40.9)
     Other 7 (31.8)
Disease duration at the time of RTX therapy, median (IQR)- months 13.5 (0.8-25.8)
Indication for RTX therapy, n (%)
     Refractory disease 8 (36.4)
     Relapsing disease 8 (36.4)
     Contraindications to conventional steroid/IS therapy 6 (27.3)
RTX schedule, n (%)
     375 mg/m2/week x4 15 (68.2)
     1 g x2 (two weeks apart) 7 (31.8)
Data are presented as n(%) or median (interquartile range, IQR)
¶Kidney biopsy findings are classified according to Pillebout et al. (ref #2)
* one patient had pancreatic involvement
Abbreviations used in the table. IQR: interquartile range; BVAS: Birmingham Vasculitis Activity 
Score; eGFR: estimated glomerular filtration rate; CKD-EPI: chronic kidney disease 
epidemiology collaboration; RTX: Rituximab; IS: immunosuppressive
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Table 2. Frequencies of organ involvement and main disease parameters at different time-points
Time after RTX treatment
Baseline
n=22
Month 1
n=22
Month 6
n=22
Month 12
n=22
Active organ involvement, n (%)
     Skin 18 (81.8) 5 (22.7) 1 (4.5) 3 (13.6)
     Gastro-intestinal 15 (68.2) 0 2 (9.1) 1 (4.5)
     Kidney 18 (81.8) 13 (59.1) 3 (13.6) 3 (13.6)
     Joint (arthritis/arthralgia) 16 (72.7) 4 (18.2) 2 (9.1) 1 (4.5)
BVAS, median (IQR) 15.0 (9.5–19.8) 6.0 (4.5-8.5) 5.0 (4.5-10.5) 5.0 (1.5-8.0)
eGFR (CKD-EPI), median (IQR)- ml/min/1.73m2 82.0 (65.0–101.0) 92.0 (54.0-98.5) 78.0 (66.2-90.7) 77.0 (60.0-106.0)
Proteinuria, median (IQR)- mg/24h 1700 (750 – 2375) 1730 (618-3708) 479 (150-3000) 493 (100-1000)
Concomitant treatments, n (%)
     Glucocorticoids and/or immunosuppressants 16 (72.7) 11 (50.0) 6 (27.3) 4 (18.2)
     Glucocorticoids 15 (68.2) 11 (50.0) 6 (27.3) 4 (18.2)
     Immunosuppressants 7 (31.8) 5 (22.7) 4 (18.2) 4 (18.2)
Patients in remission, n (%) - 10 (45.5) 16 (72.7) 16 (72.7)
Abbreviations used in the table. RTX: Rituximab; BVAS: Birmingham Vasculitis Activity Score; IQR: interquartile range; eGFR: estimated glomerular 
filtration rate; CKD-EPI: chronic kidney disease epidemiology collaboration 
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FIGURE LEGENDS
Figure  1.  Variations  in  Birmingham  Vasculitis  Activity  Score  (BVAS),  C-reactive  protein
(CRP)  levels,  prednisone  dose,  estimated  glomerular  filtration  rate  (eGFR)  and  24h-
proteinuria  throughout  the study period.  Significant  reductions in  BVAS (p<0.0001),  CRP
(p=0.0005), prednisone dose (p<0.0001) and 24h-proteinuria (p<0.0001) were observed after
RTX therapy. No significant  change of  eGFR was found (p=0.59).  These variations were
calculated using Friedman’s test and corrected using Dunn’s test for multiple comparisons.
In the plots, the boxes indicate the 25th-75th percentile, the bar inside the boxes indicates the
median, the whiskers indicate the 10th-90th percentile, and the dots the outliers.
Abbreviations: BVAS: Birmingham Vasculitis Activity Score; eGFR: estimated glomerular 
filtration rate. t0, t1, t6, t12, last-fu denote respectively the time of Rituximab therapy, month 
1, month 6, month 12 and last follow-up.
Supplementary figure 1. Variations in total IgA serum levels throughout the study period. 
Serum IgA levels slightly but significantly declined over time (p=0.03 using Friedman’s test)
Supplementary figure 2.  Immunohistochemical characterisation of the main inflammatory
cell  types  in  renal  and  skin  lesions  from patients  with  IgA vasculitis.  The  images  show
representative findings obtained from 3 renal biopsies and 3 skin biopsies of patients with
adult-onset IgA vasculitis. Renal biopsy findings are shown in figures A, C, E, G and I, and
skin biopsy findings in figures B, D, F, H and J. A and C show endo- and extra-capillary
glomerulonephritis  with  dominant  IgA  deposits  at  immunofluorescence.  At
immunohistochemical analysis, the main infiltrating cells are CD163+ macrophages (E), and
CD3+ T-cells  (G),  whereas CD20+ B-cells  are  scarce (I).  B  and D show leukocytoclastic
vasculitis  of  the  skin  with  dominant  IgA  deposits  at  immunofluorescence.  At
immunohistochemical analysis, the main infiltrating cells are CD163+ macrophages (F), and
CD3+ T-cells (H), whereas CD20+ B-cells are absent (J).
A,  B:  haematoxylin  and  eosin,  original  magnification  x20,  bar  200  um.  C,  D:
immunofluorescence staining using anti-IgA antibodies; original magnifications x40 (C), x20
(D),  bar 200 um (C),  150 um (D).  E,  F:  immunohistochemical  staining using anti-CD163
antibody, original  magnification  x20.  G,  H:  immunohistochemical  staining  using  anti-CD3
antibody,  original  magnification  x20.  I,  J:  immunohistochemical  staining  using  anti-CD20
antibody, original magnification x20
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